ASCO 2023: Targeted therapy achieves responses across multiple cancer types with FGFR alterations
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center…
Browsing: Featured
ASCO 2023: Antibody-microtubule inhibitor conjugate improves survival in women with recurrent ovarian cancer
MIRASOL, an international phase III randomised clinical trial, found that mirvetuximab soravtansine, an antibody and…
ASCO 2023: Trastuzumab deruxtecan effectively treats HER2-expressing cancers regardless of tumour location
Trastuzumab deruxtecan (marketed as Enhertu) is an effective treatment option for people with difficult-to-treat HER2-expressing…
ASCO 2023: Radiation can be safely omitted in select patients with locally advanced rectal cancer
“We’ve reached a tipping point in treating patients with rectal cancer. As we develop new…
ChatGPT: Will it revolutionise cancer patient information? Part 2
Did you know Artificial Intelligence can pass medical school entrance exams? How will ChatGPT revolutionise…
ChatGPT: Will it revolutionise cancer patient information? Part 1
What is ChatGPT? Will it revolutionise the way patients find healthcare information? How does it…
Spanish researchers identify a pigment present in the Santa Pola salt flats as an anticarcinogenic agent
The University of Alicante Applied Biochemistry research group—in collaboration with researchers from the Alicante University Hospital Dr.…
Plants remove cancer causing toxins from air
A ground-breaking study has revealed that plants can efficiently remove toxic gasoline fumes, including cancer causing…
Funding boost advances research on cancer vaccine
New research that could lead to a vaccine for patients with hard-to-treat cancers has been…
RANZCR welcomes Medicare funding for game-changing breast marker clips
The Royal Australian and New Zealand College of Radiologists (RANZCR) is excited to confirm that…